Anzeige
Mehr »
Montag, 21.09.2026 - Börsentäglich über 12.000 News
Auf diese Liste kann man sich nicht einkaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
25.08.Capricor secures reprieve as FDA extends DMD cell therapy review
24.08.TME holds onto $1B dream for brain cancer drug as search for partners nears conclusion
24.08.Spruce's successful FDA talks plant seeds for Q4 filing of ultra-rare disease drug
24.08.Regenxbio gene therapy refiling plan derailed by FDA hold over spine MRI findings
24.08.Roche pens $2.5B pact for Hanmi's clinical-stage obesity drug targeting less-explored mechanism
21.08.Werewolf Therapeutics transforms into Ambros Therapeutics via reverse merger to support phase 3 push for rare disease drug
20.08.Lilly pens deal with Gateway Labs alumni Amplitude for RNA vaccine platform for infectious disease
20.08.Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
19.08.Trump looks set to tap White House aide Heidi Overton as next FDA commissioner
19.08.Tolerance Bio jumps into phase 2 with $260M deal for thymus-targeting fusion protein
18.08.Merck and Sarah Cannon team up to boost oncology trial efficiency
18.08.Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss
18.08.BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca
17.08.Regeneron ends eye disease trial for anti-CD3 antibody following safety review
17.08.Merck KGaA lays off 20 staffers in latest blow to US research team
17.08.Slate Medicines uses Fulcrum Therapeutics to vault onto Nasdaq with $245M financing for migraine trials
17.08.Evaxion scraps solid tumor vaccine to focus on Duke-partnered brain cancer candidate
17.08.Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague
17.08.AstraZeneca ends phase 3 lung cancer trial after bispecific falls short versus Keytruda
14.08.Skye and Redx form new entity with $125M to advance fibrosis assets
14.08.'We're not afraid of competition': BioCryst CEO sets out strategy after scrapping internal discovery
14.08.Capricor soars on plan to amend DMD filing after adcomm setback
14.08.MapLight dims preclinical programs to make phase 3-ready schizophrenia drug shine brighter
13.08.PDS halts work on phase 3 cancer therapy to focus on colorectal contender
13.08.PTC's $211M bid wins Sangamo auction, teeing up 'special opportunity' to enter Fabry market